YM Biosciences Inc has concluded a bought financing deal for gross proceeds of $23 million. The Mississauga ON-based firm will receive the financing from a syndicate led by Dundee Securities Corp and including Canaccord Capital Corp, Dlouhy Merchant Group and Haywood Securities. The proceeds will be used primarily to finance pivotal Phase III clinical trials for tesmilifene, a small molecule chemopotentiator for metastatic breast cancer and its le
Other stories mentioning these organizations, people and topics
| Organizations: | Canaccord Capital Corp, Dlouhy Merchant Group, Dundee Securities Corp, Haywood Securities, and YM Biosciences Inc |
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 1 free article remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.